NCT04604704 is a Phase 2 clinical trial of Naltrexone in Covid19, sponsored by AgelessRx.

Who is sponsoring NCT04604704?

NCT04604704 is sponsored by AgelessRx.

What drugs are being tested in NCT04604704?

Interventions in NCT04604704: Naltrexone, NAD+.

What condition does NCT04604704 study?

NCT04604704 studies Covid19, Long COVID-19, Post-COVID-19 Syndrome.

Is NCT04604704 still recruiting?

NCT04604704 is currently completed. Last updated 25 January 2023.

Last reviewed 2023-01-25 · How we verify

NCT04604704

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

Completed Phase 2 Last updated 25 January 2023

What this trial tests

Phase 2 trial testing Naltrexone in Covid19 in 36 participants. Completed in 23 January 2023.

Timeline

28 January 2021

Primary endpoint
23 January 2023

23 January 2023

Quick facts

Lead sponsor	AgelessRx
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	28 January 2021
Primary completion	23 January 2023
Estimated completion	23 January 2023
Sites	1 location across United States

Drugs / interventions tested

Naltrexone — full drug profile →
NAD+ (NAD+) — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
Long COVID-19 — all drugs for Long COVID-19 →
Post-COVID-19 Syndrome — all drugs for Post-COVID-19 Syndrome →

Sponsor

AgelessRx — full company profile →

Who can join

Adults 18 to 65, any sex, with Covid19 or Long COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Post-COVID-19 Syndrome and the Potential Benefits of Exercise.
Jimeno-Almazán A, Pallarés JG, Buendía-Romero Á, Martínez-Cava A, et al · · 2021 · cited 176× · PMID 34067776 · DOI 10.3390/ijerph18105329
Long COVID and its Management.
Koc HC, Xiao J, Liu W, Li Y, et al · · 2022 · cited 153× · PMID 35874958 · DOI 10.7150/ijbs.75056
Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome.
Sukocheva OA, Maksoud R, Beeraka NM, Madhunapantula SV, et al · · 2022 · cited 118× · PMID 36100326 · DOI 10.1016/j.jare.2021.11.013
The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID.
Li J, Zhou Y, Ma J, Zhang Q, et al · · 2023 · cited 91× · PMID 37907497 · DOI 10.1038/s41392-023-01640-z
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative.
Bonilla H, Peluso MJ, Rodgers K, Aberg JA, et al · · 2023 · cited 72× · PMID 36969241 · DOI 10.3389/fimmu.2023.1129459
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Clinical trials on the pharmacological treatment of long COVID: A systematic review.
Chee YJ, Fan BE, Young BE, Dalan R, et al · · 2023 · cited 55× · PMID 36349400 · DOI 10.1002/jmv.28289
Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.
O'Kelly B, Vidal L, McHugh T, Woo J, et al · · 2022 · cited 50× · PMID 35814187 · DOI 10.1016/j.bbih.2022.100485

Verify or expand the search:

Other trials of Naltrexone

Trials testing the same drug.

NCT07433413 — Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder · Phase 3 · not yet recruiting
NCT06622239 — Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury · Phase 2 · not yet recruiting
NCT06426303 — Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Di · Phase 4 · recruiting
NCT05968690 — Naltrexone and Propranolol Combined With Immunotherapy · Phase 1 · recruiting
NCT05458609 — Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep · Phase 3 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other AgelessRx trials

Trials by the same sponsor.

NCT07092605 — Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures · EARLY_PHASE1 · enrolling by invitation
NCT06301529 — The Efficacy and Tolerability of Canagliflozin in Healthy Individual · Phase 4 · completed
NCT06550271 — The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals · completed
NCT05542849 — The Efficacy and Tolerability of Acarbose in Healthy Individuals · Phase 4 · completed
NCT05307627 — The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04604704 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AgelessRx
Last refreshed: 25 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04604704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing